Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyUrapidil
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Name
- Urapidil
- Accession Number
- DB12661
- Type
- Small Molecule
- Groups
- Investigational
- Description
Urapidil has been investigated for the treatment of Hypertension During Pre-Eclampsia.
- Structure
- Synonyms
- Not Available
- Categories
- Adrenergic Agents
- Adrenergic alpha-1 Receptor Antagonists
- Adrenergic alpha-Antagonists
- Adrenergic Antagonists
- Agents that produce hypertension
- Antiadrenergic Agents, Peripherally Acting
- Antihypertensive Agents
- Cardiovascular Agents
- Central Nervous System Depressants
- Neurotransmitter Agents
- Serotonin Agents
- Serotonin Receptor Agonists
- Vasodilating Agents
- UNII
- A78GF17HJS
- CAS number
- 34661-75-1
- Weight
- Average: 387.484
Monoisotopic: 387.227039814 - Chemical Formula
- C20H29N5O3
- InChI Key
- ICMGLRUYEQNHPF-UHFFFAOYSA-N
- InChI
- InChI=1S/C20H29N5O3/c1-22-18(15-19(26)23(2)20(22)27)21-9-6-10-24-11-13-25(14-12-24)16-7-4-5-8-17(16)28-3/h4-5,7-8,15,21H,6,9-14H2,1-3H3
- IUPAC Name
- 6-({3-[4-(2-methoxyphenyl)piperazin-1-yl]propyl}amino)-1,3-dimethyl-1,2,3,4-tetrahydropyrimidine-2,4-dione
- SMILES
- COC1=CC=CC=C1N1CCN(CCCNC2=CC(=O)N(C)C(=O)N2C)CC1
Pharmacology
- Indication
- Not Available
- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half life
- Not Available
- Clearance
- Not Available
- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction (R)-warfarin The risk or severity of adverse effects can be increased when Urapidil is combined with (R)-warfarin. (S)-Warfarin The risk or severity of adverse effects can be increased when Urapidil is combined with (S)-Warfarin. 1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic Acid 1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic Acid may increase the hypotensive activities of Urapidil. 1-benzylimidazole The risk or severity of hypertension can be increased when 1-benzylimidazole is combined with Urapidil. 2,5-Dimethoxy-4-ethylamphetamine The therapeutic efficacy of Urapidil can be decreased when used in combination with 2,5-Dimethoxy-4-ethylamphetamine. 2,5-Dimethoxy-4-ethylthioamphetamine The therapeutic efficacy of Urapidil can be decreased when used in combination with 2,5-Dimethoxy-4-ethylthioamphetamine. 3,4-Methylenedioxyamphetamine The therapeutic efficacy of Urapidil can be decreased when used in combination with 3,4-Methylenedioxyamphetamine. 4-Bromo-2,5-dimethoxyamphetamine The therapeutic efficacy of Urapidil can be decreased when used in combination with 4-Bromo-2,5-dimethoxyamphetamine. 4-hydroxycoumarin The risk or severity of adverse effects can be increased when Urapidil is combined with 4-hydroxycoumarin. 4-Methoxyamphetamine The therapeutic efficacy of 4-Methoxyamphetamine can be decreased when used in combination with Urapidil. - Food Interactions
- Not Available
References
- General References
- Not Available
- External Links
- ATC Codes
- C02CA06 — Urapidil
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 1 Recruiting Treatment Aortic Dissection Type B / High Blood Pressure (Hypertension) 1 3 Recruiting Treatment High Blood Pressure (Hypertension) / Preeclampsia 1 3 Unknown Status Treatment Hypertension During Pre-Eclampsia 1 4 Recruiting Treatment Nontraumatic Intracerebral Hemorrhage, Multiple Localized 1 Not Available Completed Treatment CVA (Cerebrovascular Accident) / Intracerebral Hemorrhage / Intracranial Hemorrhages 1 Not Available Recruiting Diagnostic General Surgery 1 Not Available Recruiting Treatment Aging / Anaesthesia therapy / Blood Loss,Surgical / Blood Pressures / General Surgery / Postoperative Delirium 1 Not Available Recruiting Treatment Scheduled Laparoscopic Surgery 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.541 mg/mL ALOGPS logP 1.69 ALOGPS logP 1.18 ChemAxon logS -2.9 ALOGPS pKa (Strongest Basic) 8.11 ChemAxon Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 6 ChemAxon Hydrogen Donor Count 1 ChemAxon Polar Surface Area 68.36 Å2 ChemAxon Rotatable Bond Count 7 ChemAxon Refractivity 119.37 m3·mol-1 ChemAxon Polarizability 43.07 Å3 ChemAxon Number of Rings 3 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule Yes ChemAxon - Predicted ADMET features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available LC-MS/MS Spectrum - LC-ESI-qTof , Positive LC-MS/MS Not Available MS/MS Spectrum - , positive LC-MS/MS splash10-000i-0439000000-1f066af9035f53bb2d89 MS/MS Spectrum - , positive LC-MS/MS splash10-0006-0900000000-2ccc838e7c2c252cb8ad
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as phenylpiperazines. These are compounds containing a phenylpiperazine skeleton, which consists of a piperazine bound to a phenyl group.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Diazinanes
- Sub Class
- Piperazines
- Direct Parent
- Phenylpiperazines
- Alternative Parents
- N-arylpiperazines / Aminophenyl ethers / Methoxyanilines / Anisoles / Dialkylarylamines / Methoxybenzenes / Phenoxy compounds / N-alkylpiperazines / Aminopyrimidines and derivatives / Alkyl aryl ethers show 12 more
- Substituents
- Phenylpiperazine / N-arylpiperazine / Aminophenyl ether / Methoxyaniline / Tertiary aliphatic/aromatic amine / Phenoxy compound / Anisole / Dialkylarylamine / Aniline or substituted anilines / Phenol ether show 28 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- Not Available
Drug created on October 20, 2016 17:31 / Updated on November 02, 2018 07:28